Trial Profile
A Time-window StratifiedRandomised, Open-label, Controlled, Multicentered Phase IIa Trial to Assess the Efficacy and Safety of Thrombolysis with Recombinant Human Prourokinase in the patients with Acute Acute Ischaemic Stroke
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Dec 2023
Price :
$35
*
At a glance
- Drugs Urokinase (Primary)
- Indications Stroke
- Focus Therapeutic Use
- Acronyms rhpro-UK STROKEIIa
- Sponsors Shanghai Tasly Pharmaceutical
- 29 Nov 2023 Primary endpoint [modified Rankin scale (mRS) score Group A (rhPro-UK 50 mg) vs Group B (rhPro-UK 35 mg) assessed 4.5h to 6h of AIS onset] has not been met as per results published in the CNS Drugs.
- 29 Nov 2023 Results (n= 80) of this trial evaluating therapeutic effects and safety of intravenous recombinant human prourokinase (rhPro-UK) in patients with acute ischemic stroke (AIS) in the 4.5-6 h therapeutic time windows published in the CNS Drugs.
- 08 Feb 2019 Preliminary results presented at the International Stroke Conference 2019